Factor ix

Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: IV Replacement therapy in haemophilia B Human plasma-derived or recombinant: Dosage and duration depends on the preparation used, severity of the disease and type of surgery to be performed. Suggested target factor IX concentrations: Mild to moderate haemorrhage: Increase to 20-40% of normal. More serious haemorrhage or minor surgery: Increase to 30-60% of normal. Severe haemorrhage or major surgery: Increase to 60-100% of normal. Prophylaxis in severe haemophilia B Human plasma-derived: 20-40 IU/kg every 3-4 days as required. Recombinant: As nonacog alfa: 40 IU/kg (range 13 to 78 IU/kg) every 3-4 days. As nonacog gamma: 40-60 IU/kg every 3-4 days. As albutrepenonacog alfa: 35-50 IU/kg once wkly, or up to 75 IU/kg every 10 or 14 days in some patients. As eftrenonacog alfa: 50 IU/kg once wkly or 100 IU/kg once every 10 days, adjust based on response.
Hypersensitivity to factor IX or hamster protein. Disseminated intravascular coagulation, signs of fibrinolysis.
Special Precautions
Patient at risk of thromboembolism or disseminated intravascular coagulation (DIC). Hepatic impairment. Childn. Pregnancy and lactation. Monitoring Parameters Measure factor IX levels 15 min after infusion. Monitor aPTT, BP, heart rhythm. Monitor for signs of bleeding, DIC, or thromboembolic complications. Perform screening for factor IX inhibitors if patient experiences hypersensitivity reaction, will undergo surgery, or if suboptimal response to treatment occur.
Adverse Reactions
Significant: Disseminated intravascular coagulation, thromboembolism (e.g. arterial or venous thrombosis, pulmonary embolism), hypotension, bronchospastic reactions, nephrotic syndrome (in patients w/ factor IX inhibitors), antibody formation. Nervous: Headache, dizziness, drowsiness. GI: Nausea, vomiting, dysgeusia. Resp: Dyspnoea. Dermatologic: Hives, rash, urticaria. Others: Fever, chills, lethargy, flushing; pain, stinging, or burning at inj site.
Potentially Fatal: Anaphylaxis.
CIMS Class
Disclaimer: This information is independently developed by CIMS based on factor ix from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in